(Q37127245)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

F Cervantes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

G Barosi

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

3 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

905-914

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18385755%20AND%20SRC:MED&resulttype=core&format=json

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Age and sex distributions of hematological malignancies in the U.K.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

A prognostic classification of myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Idiopathic myelofibrosis: a clinical study of 80 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Prognostic factors in idiopathic (Primary) osteomyelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Life expectancy of patients with chronic nonleukemic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Long-term survival of infants with idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Anaemia in myelofibrosis: its value in prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Agnogenic myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Erythrokinetic studies in myelofibrosis: their significance for prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Long-term use of anagrelide in young patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Essential thrombocythemias. Clinical evolutionary and biological data

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Clinical course of essential thrombocythemia in 147 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

How I treat patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

When and how to treat essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Efficacy and safety of low-dose aspirin in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.72

7 January 2021